Clinical significance of 4 L lymphadenectomy in solid dominant clinical stage I non-small cell lung cancer in the left upper lobe

被引:0
|
作者
Watanabe, Yukio [1 ]
Hattori, Aritoshi [1 ]
Fukui, Mariko [1 ]
Matsunaga, Takeshi [1 ]
Takamochi, Kazuya [1 ]
Suzuki, Kenji [1 ]
机构
[1] Juntendo Univ, Sch Med, Dept Gen Thorac Surg, 1-3 Hongo 3 Chome,Bunkyo Ku, Tokyo 1138421, Japan
关键词
non-small cell lung cancer; clinical stage I; solid dominant; 4 L lymphadenectomy; LYMPH-NODE DISSECTION; SURVIVAL; SURGERY;
D O I
10.1093/jjco/hyaf032
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The significance of station 4 L lymph node dissection (LND) for early-stage non-small cell lung cancer (NSCLC) is unknown. Methods: We evaluated 342 patients who underwent complete anatomical resection and mediastinal LND for radiologically solid dominant clinical (c)-Stage I left upper lobe NSCLC between 2008 and 2022. Solid dominant was defined as a consolidation tumor ratio >0.5, on thin-section computed tomography. After matching, postoperative complications and outcomes between the 4 L LND and non-4 L LND groups were compared. Predictors of 4 L metastasis was also identified using logistic regression analysis. Results: 4LND was performed in 215 patients (63%), and 4 L metastasis was detected in 11 patients. Matching yielded 108 pairs. Recurrent nerve paralysis was more frequent in the 4LND group (P = 0.02) with no significant differences in the overall survival (OS) (5y OS: 85.2% vs. 86.3%, P = 0.66) and recurrence-free survival (RFS) (5y RFS: 78.4% vs. 78.5%, P = 0.51) between the 4 L LND and non-4 L LND groups. Logistic regression analysis determined solid component size >20 mm (P = 0.02) and pleural indentation (P = 0.02) on computed tomography findings as clinical risk factors for 4 L metastasis. The predictive criteria for 4 L metastasis were defined as solid component size <= 20 mm without pleural indentation (specificity: 100%, positive predictive value: 100%). Conclusions: 4 L LND had a higher frequency of recurrent nerve palsy, although no survival improvement was observed in solid dominant c-Stage I left upper NSCLC. 4 L LND may be omitted for solid component size <= 20 mm without pleural indentation.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Clinical Significance of Expression of Periostin in Non-small Cell Lung Cancer
    Qiao, Zhixiong
    Zhang, Lan
    He, Jinxi
    He, Wei
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (09): : 1149 - 1153
  • [22] Prognostic Significance of Lymphovascular Invasion for Patients with Stage I Non-Small Cell Lung Cancer
    Hanagiri, T.
    Takenaka, M.
    Oka, S.
    Shigematsu, Y.
    Nagata, Y.
    Shimokawa, H.
    Uramoto, H.
    Yamada, S.
    Tanaka, F.
    EUROPEAN SURGICAL RESEARCH, 2011, 47 (04) : 211 - 217
  • [23] Expression patterns and clinical significance of estrogen receptor in non-small cell lung cancer
    Castellanos, Mario R.
    Fanous, Ereeny
    Thaker, Rina
    Flory, Michael J.
    Seetharamu, Nagashree
    Dhar, Meekoo
    Starr, Adam
    Strange, Theodore J.
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 241
  • [24] Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer
    Maeda, Ryo
    Suda, Takashi
    Hachimaru, Ayumi
    Tochii, Daisuke
    Tochii, Sachiko
    Takagi, Yasushi
    JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : 176 - 186
  • [25] Lobectomy plus lobe-specific lymphadenectomy as the minimum standards of curative resection for hypermetabolic clinical stage IA non-small cell lung cancer
    Li, Runze
    Li, Zhifei
    Li, Peng
    Chen, Jianchuan
    Qiu, Bin
    Tan, Fengwei
    Xue, Qi
    Gao, Shugeng
    He, Jie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (01) : 14 - 26
  • [26] A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non-small cell lung cancer
    Deng, Jiajun
    Zhao, Mengmeng
    Wang, Tingting
    She, Yunlang
    Wu, Junqi
    Haoran, E.
    Gao, Jiani
    Sun, Xiwen
    Jiang, Gening
    Zhu, Yuming
    Xie, Dong
    Chen, Chang
    LUNG CANCER, 2020, 145 : 33 - 39
  • [27] Clinical Significance of Prostate Stem Cell Antigen Expression in Non-small Cell Lung Cancer
    Kawaguchi, Takeshi
    Sho, Masayuki
    Tojo, Takashi
    Yamato, Ichiro
    Nomi, Takeo
    Hotta, Kiyohiko
    Hamada, Kaoru
    Suzaki, Yasue
    Sugiura, Shigeki
    Kushibe, Keiji
    Nakajima, Yoshiyuki
    Taniguchi, Shigeki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (04) : 319 - 326
  • [28] Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non-Small Cell Lung Cancer
    Heiden, Brendan T.
    Eaton, Daniel B., Jr.
    Engelhardt, Kathryn E.
    Chang, Su-Hsin
    Yan, Yan
    Patel, Mayank R.
    Kreisel, Daniel
    Nava, Ruben G.
    Meyers, Bryan F.
    Kozower, Benjamin D.
    Puri, Varun
    JAMA NETWORK OPEN, 2021, 4 (05)
  • [29] Clinical Significance of Expression of Cancer/testis Antigen and Down-regulation of HLA Class-I in Patients with Stage I Non-small Cell Lung Cancer
    Hanagiri, Takeshi
    Shigematsu, Yoshiki
    Shinohara, Shinji
    Takenaka, Masaru
    Oka, Sohich
    Chikaishi, Yasuhiro
    Nagata, Yoshika
    Baba, Tetsuro
    Uramoto, Hidetaka
    So, Tomoko
    Yamada, Sohsuke
    ANTICANCER RESEARCH, 2013, 33 (05) : 2123 - 2128
  • [30] Outcome After Surgical Resection for Clinical Stage I Non-Small Cell Lung Cancer Associated with Interstitial Lung Disease
    Koizumi, T.
    Hirono, T.
    Watanabe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S617 - S617